DE60217140D1 - N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n-phenylamine als antiproliferative verbindungen - Google Patents

N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n-phenylamine als antiproliferative verbindungen

Info

Publication number
DE60217140D1
DE60217140D1 DE60217140T DE60217140T DE60217140D1 DE 60217140 D1 DE60217140 D1 DE 60217140D1 DE 60217140 T DE60217140 T DE 60217140T DE 60217140 T DE60217140 T DE 60217140T DE 60217140 D1 DE60217140 D1 DE 60217140D1
Authority
DE
Germany
Prior art keywords
methylthiazol
phenylamine
pyrimidin
antiproliferative compounds
antiproliferative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60217140T
Other languages
English (en)
Other versions
DE60217140T2 (de
Inventor
Shudong Wang
Christopher Meades
Gavin Wood
Andrew Osnowski
Peter Martin Fischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclacel Ltd
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0123377A external-priority patent/GB0123377D0/en
Priority claimed from GB0123629A external-priority patent/GB0123629D0/en
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Publication of DE60217140D1 publication Critical patent/DE60217140D1/de
Application granted granted Critical
Publication of DE60217140T2 publication Critical patent/DE60217140T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Refuge Islands, Traffic Blockers, Or Guard Fence (AREA)
DE60217140T 2001-09-28 2002-09-27 N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n-phenylamine als antiproliferative verbindungen Expired - Lifetime DE60217140T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0123377 2001-09-28
GB0123377A GB0123377D0 (en) 2001-09-28 2001-09-28 Anticancer compounds
GB0123629A GB0123629D0 (en) 2001-10-02 2001-10-02 Anticancer compounds
GB0123629 2001-10-02
PCT/GB2002/004383 WO2003029248A1 (en) 2001-09-28 2002-09-27 N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl) -n-phenylamines as antiproliferative compounds

Publications (2)

Publication Number Publication Date
DE60217140D1 true DE60217140D1 (de) 2007-02-08
DE60217140T2 DE60217140T2 (de) 2007-04-19

Family

ID=26246590

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60217140T Expired - Lifetime DE60217140T2 (de) 2001-09-28 2002-09-27 N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n-phenylamine als antiproliferative verbindungen

Country Status (13)

Country Link
US (2) US7388015B2 (de)
EP (2) EP1430051B1 (de)
JP (1) JP4495963B2 (de)
CN (1) CN100500663C (de)
AT (1) ATE349443T1 (de)
BR (1) BR0212944A (de)
CA (1) CA2460909A1 (de)
CZ (1) CZ2004354A3 (de)
DE (1) DE60217140T2 (de)
IL (1) IL161092A0 (de)
MX (1) MXPA04002914A (de)
NZ (1) NZ531596A (de)
WO (1) WO2003029248A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
CA2439440A1 (en) 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0313511D0 (en) * 2003-06-11 2003-07-16 Cyclacel Ltd Combination
EP1678171B1 (de) 2003-10-21 2016-09-14 Cyclacel Limited 2-amino-4-thiazolon-pyrimidinderivate als proteinkinaseinhibitoren
WO2005040135A1 (ja) * 2003-10-24 2005-05-06 Ono Pharmaceutical Co., Ltd. 抗ストレス薬およびその医薬用途
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
GB0411791D0 (en) * 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
US20080125404A1 (en) * 2004-08-27 2008-05-29 Cyclacel Limited Purine and Pyrimidine Cdk Inhitbitors and Their use for The Treatment of Autoimmune Diseases
KR20070083836A (ko) * 2004-10-28 2007-08-24 아이알엠 엘엘씨 헷지혹 경로 조절제로서의 화합물 및 조성물
CN101115749B (zh) * 2004-12-17 2011-06-22 安姆根有限公司 氨基嘧啶化合物和使用方法
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
GB0520958D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
US7514566B2 (en) * 2006-01-18 2009-04-07 Amgen, Inc. Thiazole compounds and methods of use
ES2437595T3 (es) 2007-12-20 2014-01-13 Novartis Ag Derivados de tiazol usados como inhibidores de la PI 3 quinasa
EP2100894A1 (de) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidinone verwendbar als Plk1 (polo-like kinase) Hemmen
GB0805477D0 (en) * 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US8293753B2 (en) * 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
CN101928258B (zh) * 2010-08-18 2014-10-29 杭州民生药业有限公司 1-(2-取代苯胺基-4-甲基-噻唑-5)-3-取代苯基-丙烯酮衍生物、制备方法及其制药用途
CN103058949A (zh) * 2011-10-18 2013-04-24 华东理工大学 做为dhodh抑制剂的噻唑衍生物及其应用
US20130184280A1 (en) * 2011-12-21 2013-07-18 Telik, Inc. Substituted thiazoles as vegfr2 kinase inhibitors
CN105267214B (zh) * 2014-07-21 2019-04-30 沈阳化工研究院有限公司 N-杂芳基苯胺类化合物作为制备抗肿瘤药物的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG47583A1 (en) 1986-01-13 1998-04-17 American Cyanamid Co 4,5,6-Substituted-n- (substituted-phenyl) -2- pyrimidinamines
EP0672035A1 (de) 1993-10-01 1995-09-20 Novartis AG Pyrimidinaminderivate und verfahren zu deren herstellung
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CN100355751C (zh) * 2000-03-29 2007-12-19 西克拉塞尔有限公司 2－取代的4－杂芳基－嘧啶、其组合物及其用途

Also Published As

Publication number Publication date
EP1430051A1 (de) 2004-06-23
EP1430051B1 (de) 2006-12-27
EP1760082A1 (de) 2007-03-07
US7427627B2 (en) 2008-09-23
JP4495963B2 (ja) 2010-07-07
ATE349443T1 (de) 2007-01-15
NZ531596A (en) 2005-08-26
JP2005508931A (ja) 2005-04-07
IL161092A0 (en) 2004-08-31
CZ2004354A3 (cs) 2004-06-16
CN1617870A (zh) 2005-05-18
CN100500663C (zh) 2009-06-17
DE60217140T2 (de) 2007-04-19
US20040259894A1 (en) 2004-12-23
BR0212944A (pt) 2004-10-13
CA2460909A1 (en) 2003-04-10
US20060199830A1 (en) 2006-09-07
US7388015B2 (en) 2008-06-17
WO2003029248A1 (en) 2003-04-10
MXPA04002914A (es) 2005-06-20

Similar Documents

Publication Publication Date Title
DE60217140D1 (de) N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n-phenylamine als antiproliferative verbindungen
ATE373653T1 (de) Pyrimidine verbindungen
DE60220771D1 (de) Hemmer von cyclinabhängigen kinasen als mittel gegen krebs
MY140291A (en) Sulfoximine-substituted pyrimidines for use as cd and/or vegf inhibitors, the production thereof and their use as drugs
ATE520663T1 (de) Stickstoff atom enthaltenden heteroaryl- harnstoffe als inhibitoren der p38-kinase
ATE339418T1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
ATE466581T1 (de) Verbindungen auf pyrimidin-basis als gsk-3-hemmer
ATE454378T1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
NL300357I2 (nl) Beta-amino tetrahydroimidazo (1,2-A)pyrazines en
DK1347971T3 (da) Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
NO20074964L (no) Pyrimidinderivater for behandling av hyperproliferative forstyrrelser
DK2201840T3 (da) Hæmmere af Brutons tyrosinkinase
CY1110742T1 (el) Αναστολεις ινδαζολης, βενζισοξαζολης, και βενζισοθειαζολης
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
DE602004032522D1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
ATE341545T1 (de) Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
YU21404A (sh) Supstituisana jedinjenja benzimidazola i njihova primena u lečenju raka
IS6925A (is) Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns
ATE279410T1 (de) 3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen
NO20054723L (no) Behandling av proliferative sykdommer med epofilonderivater og straling
PT1551850E (pt) 2 oxo-voruscharina e seus derivados

Legal Events

Date Code Title Description
8364 No opposition during term of opposition